301 related articles for article (PubMed ID: 15283234)
41. Dectin-1 is required for resistance to coccidioidomycosis in mice.
Viriyakosol S; Jimenez Mdel P; Gurney MA; Ashbaugh ME; Fierer J
mBio; 2013 Feb; 4(1):e00597-12. PubMed ID: 23386437
[TBL] [Abstract][Full Text] [Related]
42. C-type lectin receptors differentially induce th17 cells and vaccine immunity to the endemic mycosis of North America.
Wang H; LeBert V; Hung CY; Galles K; Saijo S; Lin X; Cole GT; Klein BS; Wüthrich M
J Immunol; 2014 Feb; 192(3):1107-1119. PubMed ID: 24391211
[TBL] [Abstract][Full Text] [Related]
43. Deficient resistance to Coccidioides immitis following intravenous vaccination. II. Evidence against an immune tolerance mechanism.
Scalarone GM; Levine HB
Sabouraudia; 1971 Jul; 9(2):90-6. PubMed ID: 4939207
[No Abstract] [Full Text] [Related]
44. Coccidioidomycosis: a regional disease of national importance. Rethinking approaches for control.
Galgiani JN
Ann Intern Med; 1999 Feb; 130(4 Pt 1):293-300. PubMed ID: 10068388
[TBL] [Abstract][Full Text] [Related]
45. Multivalent recombinant protein vaccine against coccidioidomycosis.
Tarcha EJ; Basrur V; Hung CY; Gardner MJ; Cole GT
Infect Immun; 2006 Oct; 74(10):5802-13. PubMed ID: 16988258
[TBL] [Abstract][Full Text] [Related]
46. Th1-type immune response to a Coccidioides immitis antigen delivered by an attenuated strain of the non-invasive enteropathogen Vibrio cholerae.
Silva AJ; Benitez JA
FEMS Immunol Med Microbiol; 2005 Mar; 43(3):393-8. PubMed ID: 15708313
[TBL] [Abstract][Full Text] [Related]
47. Cholera vaccine candidate 638: intranasal immunogenicity and expression of a foreign antigen from the pulmonary pathogen Coccidioides immitis.
Silva AJ; Mohan A; Benitez JA
Vaccine; 2003 Dec; 21(32):4715-21. PubMed ID: 14585681
[TBL] [Abstract][Full Text] [Related]
48. Update on the Epidemiology of coccidioidomycosis in the United States.
McCotter OZ; Benedict K; Engelthaler DM; Komatsu K; Lucas KD; Mohle-Boetani JC; Oltean H; Vugia D; Chiller TM; Sondermeyer Cooksey GL; Nguyen A; Roe CC; Wheeler C; Sunenshine R
Med Mycol; 2019 Feb; 57(Supplement_1):S30-S40. PubMed ID: 30690599
[TBL] [Abstract][Full Text] [Related]
49. Localization within a proline-rich antigen (Ag2/PRA) of protective antigenicity against infection with Coccidioides immitis in mice.
Peng T; Shubitz L; Simons J; Perrill R; Orsborn KI; Galgiani JN
Infect Immun; 2002 Jul; 70(7):3330-5. PubMed ID: 12065470
[TBL] [Abstract][Full Text] [Related]
50. Protection of mice against Coccidioides immitis intranasal infection by vaccination with recombinant antigen 2/PRA.
Shubitz L; Peng T; Perrill R; Simons J; Orsborn K; Galgiani JN
Infect Immun; 2002 Jun; 70(6):3287-9. PubMed ID: 12011027
[TBL] [Abstract][Full Text] [Related]
51. Coccidioides immitis vaccine: potential of an alkali-soluble, water-soluble cell wall antigen.
Lecara G; Cox RA; Simpson RB
Infect Immun; 1983 Jan; 39(1):473-5. PubMed ID: 6822433
[TBL] [Abstract][Full Text] [Related]
52. Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen.
Abuodeh RO; Shubitz LF; Siegel E; Snyder S; Peng T; Orsborn KI; Brummer E; Stevens DA; Galgiani JN
Infect Immun; 1999 Jun; 67(6):2935-40. PubMed ID: 10338502
[TBL] [Abstract][Full Text] [Related]
53. The public health need and present status of a vaccine for the prevention of coccidioidomycosis.
Hector R; Rutherford GW
Ann N Y Acad Sci; 2007 Sep; 1111():259-68. PubMed ID: 17344529
[TBL] [Abstract][Full Text] [Related]
54. The present status of vaccination against coccidioidomycosis in man.
Pappagianis D; Levine HB
Am J Epidemiol; 1975 Jul; 102(1):30-41. PubMed ID: 1155435
[TBL] [Abstract][Full Text] [Related]
55. Deficient resistance to Coccidioides immitis following intravenous vaccination. 3. Humoral and cellular responses to intravenous and intramuscular doses.
Levine HB; Scalarone GM
Sabouraudia; 1971 Jul; 9(2):97-108. PubMed ID: 5111563
[No Abstract] [Full Text] [Related]
56. Vaccinated C57BL/6 mice develop protective and memory T cell responses to Coccidioides posadasii infection in the absence of interleukin-10.
Hung CY; Castro-Lopez N; Cole GT
Infect Immun; 2014 Feb; 82(2):903-13. PubMed ID: 24478103
[TBL] [Abstract][Full Text] [Related]
57. A metalloproteinase of Coccidioides posadasii contributes to evasion of host detection.
Hung CY; Seshan KR; Yu JJ; Schaller R; Xue J; Basrur V; Gardner MJ; Cole GT
Infect Immun; 2005 Oct; 73(10):6689-703. PubMed ID: 16177346
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of the proline-rich antigen of Coccidioides immitis as a vaccine candidate in mice.
Kirkland TN; Finley F; Orsborn KI; Galgiani JN
Infect Immun; 1998 Aug; 66(8):3519-22. PubMed ID: 9673228
[TBL] [Abstract][Full Text] [Related]
59. Genetic vaccination against Coccidioides immitis: comparison of vaccine efficacy of recombinant antigen 2 and antigen 2 cDNA.
Jiang C; Magee DM; Quitugua TN; Cox RA
Infect Immun; 1999 Feb; 67(2):630-5. PubMed ID: 9916069
[TBL] [Abstract][Full Text] [Related]
60. Coccidioidal pneumonia, Phoenix, Arizona, USA, 2000-2004.
Kim MM; Blair JE; Carey EJ; Wu Q; Smilack JD
Emerg Infect Dis; 2009 Mar; 15(3):397-401. PubMed ID: 19239751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
